CR20200630A - Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales - Google Patents

Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales

Info

Publication number
CR20200630A
CR20200630A CR20200630A CR20200630A CR20200630A CR 20200630 A CR20200630 A CR 20200630A CR 20200630 A CR20200630 A CR 20200630A CR 20200630 A CR20200630 A CR 20200630A CR 20200630 A CR20200630 A CR 20200630A
Authority
CR
Costa Rica
Prior art keywords
treatment
topical
anorectal diseases
amlodipine salts
amlodipine
Prior art date
Application number
CR20200630A
Other languages
English (en)
Inventor
László Ritter
László Hornok
Tamás Solymosi
Péter Matyus
Hristos Glavinas
Romána Zelko
Andrea Ujhelyi
Richárd Karpati
Original Assignee
Tavanta Therapeutics Hungary Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tavanta Therapeutics Hungary Incorporated filed Critical Tavanta Therapeutics Hungary Incorporated
Publication of CR20200630A publication Critical patent/CR20200630A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una composición farmacéutica tópica en gel de una sal de amlodipino y métodos para su uso en el tratamiento de enfermedad anorrectal.
CR20200630A 2018-06-01 2019-05-29 Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales CR20200630A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679137P 2018-06-01 2018-06-01
US201962822400P 2019-03-22 2019-03-22
PCT/IB2019/000689 WO2019229535A2 (en) 2018-06-01 2019-05-29 Topical amlodipine salts for the treatment of anorectal diseases

Publications (1)

Publication Number Publication Date
CR20200630A true CR20200630A (es) 2021-05-26

Family

ID=67928855

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200630A CR20200630A (es) 2018-06-01 2019-05-29 Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales

Country Status (18)

Country Link
US (4) US11197848B2 (es)
EP (1) EP3801460B1 (es)
JP (1) JP7530354B2 (es)
KR (1) KR20210023908A (es)
CN (1) CN112423736A (es)
AU (1) AU2019276832B2 (es)
BR (1) BR112020024395A2 (es)
CA (1) CA3102228A1 (es)
CO (1) CO2020016480A2 (es)
CR (1) CR20200630A (es)
ES (1) ES3030705T3 (es)
HU (1) HUE072422T2 (es)
IL (1) IL279121B2 (es)
MX (1) MX2020012949A (es)
NZ (1) NZ771464A (es)
PL (1) PL3801460T3 (es)
SG (1) SG11202012365QA (es)
WO (1) WO2019229535A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200630A (es) 2018-06-01 2021-05-26 Tavanta Therapeutics Hungary Incorporated Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
EP4342494A3 (en) * 2019-12-09 2024-06-05 Futura Medical Developments Limited Topical composition and methods of measuring the cooling ability of a topical composition
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE80313T1 (de) 1988-02-29 1992-09-15 Pfizer Mittel zur erhoehung des transdermalen penetrationsflusses.
WO1995006466A1 (en) 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
ATE277596T1 (de) * 1997-02-24 2004-10-15 Sla Pharma Ag Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
US8048875B1 (en) 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
BR9916162A (pt) * 1998-12-14 2001-09-04 Cellegy Pharma Inc Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
US6391869B1 (en) 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
IL129102A0 (en) * 1999-03-22 2000-02-17 J P M E D Ltd An emulsion
IL137275A0 (en) 2000-07-12 2001-07-24 Yosefus Azaria Pharmaceutical composition for the treatment of anal fissures
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
AU2003213787A1 (en) 2002-03-06 2003-09-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
WO2007039825A2 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
WO2008022032A2 (en) 2006-08-11 2008-02-21 Solvay Pharmaceuticals, Inc. Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same
KR20090074158A (ko) 2006-09-01 2009-07-06 모베르그 데르마 아베 디하이드로피리딘 칼슘 길항제를 포함하는 국소성 조성물
US20100183519A1 (en) * 2007-06-08 2010-07-22 University Of Virginia Patent Foundation Topical Poloxamer Formulations for Enhancing Microvascular Flow: Compositions and Uses Thereof
JP5072748B2 (ja) * 2007-07-10 2012-11-14 株式会社 メドレックス アムロジピンの安定な液剤とゼリー剤
CN101468001A (zh) * 2007-12-29 2009-07-01 北京瑞康医药技术有限公司 含有氨氯地平系列盐和他汀类药物的治疗组合物
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
JP2009256216A (ja) 2008-04-14 2009-11-05 Towa Yakuhin Kk 溶液状態で安定なアムロジピンベシル酸塩内服用液剤
CA2738970A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
GB0906868D0 (en) * 2009-04-21 2009-06-03 Rabin Bennie Amlodipine salt compositions
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
US10471131B2 (en) * 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
US20150141404A1 (en) 2012-05-17 2015-05-21 Contract Pharmaceuticals Limited Non-ionic vesicle formulations of calcium channel blockers
RU2592366C2 (ru) 2013-07-22 2016-07-20 Общество с ограниченной ответственностью "ХИЛИНГ ФАРМ" Фармакологическая композиция для лечения проктологических заболеваний (варианты)
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2016118040A1 (ru) 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
IT201800002413A1 (it) 2018-02-05 2019-08-05 Carmine Antropoli "composizione a base di nifedipina per uso nel trattamento delle ragadi anali e proctalgie"
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
WO2019226542A1 (en) 2018-05-22 2019-11-28 Weinberg Assa Methods for prevention and treatment of pressure ulcers caused by ischemia using contact vasodilators
CR20200630A (es) 2018-06-01 2021-05-26 Tavanta Therapeutics Hungary Incorporated Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales

Also Published As

Publication number Publication date
ES3030705T3 (en) 2025-07-01
US11197848B2 (en) 2021-12-14
SG11202012365QA (en) 2021-01-28
BR112020024395A2 (pt) 2021-03-02
JP2021526554A (ja) 2021-10-07
KR20210023908A (ko) 2021-03-04
CO2020016480A2 (es) 2021-03-19
IL279121B2 (en) 2024-06-01
US20230414591A1 (en) 2023-12-28
JP7530354B2 (ja) 2024-08-07
CN112423736A (zh) 2021-02-26
NZ771464A (en) 2024-12-20
IL279121A (en) 2021-01-31
US11766428B2 (en) 2023-09-26
US20220000850A1 (en) 2022-01-06
MX2020012949A (es) 2021-05-12
EP3801460B1 (en) 2025-03-12
EP3801460C0 (en) 2025-03-12
IL279121B1 (en) 2024-02-01
US20250064790A1 (en) 2025-02-27
US20190365732A1 (en) 2019-12-05
EP3801460A2 (en) 2021-04-14
CA3102228A1 (en) 2019-12-05
WO2019229535A3 (en) 2020-01-30
PL3801460T3 (pl) 2025-09-08
HUE072422T2 (hu) 2025-11-28
AU2019276832A1 (en) 2021-01-21
WO2019229535A2 (en) 2019-12-05
AU2019276832B2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
TN2020000001A1 (en) Carboxamides as modulators of sodium channels
TN2019000033A1 (fr) Agents thérapeutiques pour maladies neurodégénératives
WO2016133903A3 (en) Combination therapy for cancer treatment
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
MX2020012949A (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales.
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
AR103118A1 (es) Tratamientos médicos basados en anamorelina
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EP3604342A4 (en) FUSION PROTEIN, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREOF IN THE PRODUCTION OF A TREATMENT OF AN OPHTHALMIC DISEASE, ANTI-FLAMMING AND ANTITUDE MEDICINE
EA201792121A1 (ru) Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)
MX2014002817A (es) Suspension oral.
EP3834826A4 (en) THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN THE MATERNO-FETAL RELATIONSHIP
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
TW201642906A (en) Fixed dose combination for pain relief without edema
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
EA202190558A1 (ru) Новые производные тиазола и их фармацевтически приемлемые соли
MX2015009414A (es) Agentes analgesicos oculares topicos.
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
JOP20200005B1 (ar) تركيبات صيدلية
PL419074A1 (pl) Zastosowanie medyczne magnofloryny
HK40048558A (en) Topical amlodipine salts for the treatment of anorectal diseases